

## **REMARKS**

After entry of this paper, claims 1-67, 69-71, and 149-150 are pending in this case. Previously-presented claim 149 was not listed as pending in the Office Action and Applicants have assumed that the omission was a clerical error. Claims 74 and 75 have been withdrawn as directed to non-elected subject matter. Applicants reserve the right to prosecute these claims in a divisional application.

In response to the requirement to elect the claims/subject matter of one (1) group, Applicants hereby elect, without traverse, the claims of Group I, i.e., claims 1-67 and 69-71 (as well as claim 149), all of which are drawn to peptides or peptidomimetics, pharmaceutical compositions comprising same, and use of the compositions to inhibit the FP receptor. In response to the requirement to elect one (1) peptide or peptidomimetic, Applicants hereby elect the peptide of SEQ ID NO. 32. New claim 150 has been added which is directed to the elected peptidomimetic, and Applicants submit that it properly falls under the elected subject matter. The new claim is supported in the originally filed specification at page 62, Table 4, Compound No. 32. Thus, Claims 1-67, 69-71, and 149-150 read on the elections made by Applicants herein.

Applicants submit that no new matter has been introduced by virtue of the foregoing amendments to the claims. However, by virtue of the claim amendments, an additional dependent claim has been added, and the effective total number of claims has increased by one; accordingly, an additional claims filing fee, in the amount of \$25.00, as prescribed therefor by 37 C.F.R. 1.16(i), as amended, in the case of a small entity, is being submitted herewith.

Furthermore, the Commissioner is requested to construe this paper as including a retroactive petition for a three-month extension of time in which to file a response to the outstanding Office Action, and accordingly, the official fee of \$510.00, as prescribed therefor by 37 C.F.R. 1.17(a)(3), as amended, in the case of a small entity, is also being submitted herewith.

Both of the foregoing fees are being covered by a bulk check submitted herewith in the amount of \$535.00. The Commissioner is authorized to charge any additional

extension fees which may be required, or to credit any overpayment, to Deposit Account No. 07-1730.

Applicants have responded herein to the points raised by the Examiner in the Office Action. Accordingly, further favorable action in connection with this patent application is earnestly solicited. The Examiner is invited to contact the undersigned attorney by telephone if it will advance the prosecution of this case.

Respectfully submitted,

GOTTLIEB, RACKMAN & REISMAN  
Attorneys for Applicants  
270 Madison Avenue  
New York, New York 10016-0601  
(212) 684-3900

By:

A handwritten signature in black ink, appearing to read "David S. Kashman", written over a horizontal line.

David S. Kashman  
(Registration No. 28,725)

Dated: New York, New York  
June 28, 2007



## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on:

Date of Deposit June 28, 2007

David S. Kashman; Reg. No. 28,725  
(Name of applicant, assign or Registered Representative)

David S. Kashman  
(Signature)

June 28, 2007  
(Date of Signature)